Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
6.99
-0.22 (-3.05%)
Dec 15, 2025, 4:00 PM EST - Market closed
Myriad Genetics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Myriad Genetics stock have a consensus rating of "Buy" and an average price target of $11.82, which forecasts a 69.10% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $29.
Price Target: $11.82 (+69.10%)
Analyst Consensus: Buy
* Price targets were last updated on Nov 11, 2025.
Analyst Ratings
The average analyst rating for Myriad Genetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 9 | 9 | 9 | 9 | 9 | 7 |
| Sell | 3 | 3 | 3 | 3 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 14 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $8.5 | Buy | Maintains | $9 → $8.5 | +21.60% | Nov 11, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $6 → $6.5 | Hold | Maintains | $6 → $6.5 | -7.01% | Nov 5, 2025 |
| TD Cowen | TD Cowen | Hold Maintains $8 → $9 | Hold | Maintains | $8 → $9 | +28.76% | Nov 4, 2025 |
| UBS | UBS | Hold Maintains $6 → $8 | Hold | Maintains | $6 → $8 | +14.45% | Nov 4, 2025 |
| Scotiabank | Scotiabank | Buy → Hold Downgrades $20 → $6 | Buy → Hold | Downgrades | $20 → $6 | -14.16% | May 21, 2025 |
Financial Forecast
Revenue This Year
838.40M
from 837.60M
Increased by 0.10%
Revenue Next Year
882.64M
from 838.40M
Increased by 5.28%
EPS This Year
0.01
from -1.41
EPS Next Year
0.07
from 0.01
Increased by 669.21%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 867.8M | 941.1M | |||
| Avg | 838.4M | 882.6M | |||
| Low | 801.8M | 818.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.6% | 12.3% | |||
| Avg | 0.1% | 5.3% | |||
| Low | -4.3% | -2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.02 | 0.20 | |||
| Avg | 0.01 | 0.07 | |||
| Low | - | -0.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,163.8% | |||
| Avg | - | 669.2% | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.